Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hematopoiesis01:21

Hematopoiesis

9.5K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
9.5K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

4.2K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
4.2K
Overview of Hematopoiesis01:20

Overview of Hematopoiesis

10.7K
Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
10.7K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

4.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.2K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

4.0K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
4.0K
Abnormal Proliferation02:23

Abnormal Proliferation

5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

American journal of hematology·2026
Same author

Detection of MEN1 resistance mutations in cell-free DNA from acute leukemia patients treated with menin inhibitors.

Blood cancer journal·2026
Same author

Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.

Leukemia·2026
Same author

Generalist large language models complement tailor-made predictors for tumor genomics interpretation.

bioRxiv : the preprint server for biology·2026
Same author

Reinventing biotech systems for patient impact.

Nature medicine·2026
Same author

P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML.

Science advances·2026

Related Experiment Video

Updated: Mar 7, 2026

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase
10:33

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase

Published on: October 15, 2018

8.7K

TET2 in Normal and Malignant Hematopoiesis.

Robert L Bowman1, Ross L Levine1,2

  • 1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021.

Cold Spring Harbor Perspectives in Medicine
|March 1, 2017
PubMed
Summary

The ten-eleven translocation (TET) family of enzymes, crucial for DNA demethylation, are frequently mutated in cancers, especially blood cancers. This review focuses on TET2

More Related Videos

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
08:00

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

14.4K
Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells
10:25

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells

Published on: August 9, 2019

10.1K

Related Experiment Videos

Last Updated: Mar 7, 2026

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase
10:33

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase

Published on: October 15, 2018

8.7K
Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
08:00

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

14.4K
Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells
10:25

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells

Published on: August 9, 2019

10.1K

Area of Science:

  • Molecular Biology
  • Epigenetics
  • Cancer Biology

Background:

  • The ten-eleven translocation (TET) family of enzymes are key regulators of DNA demethylation, converting 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC).
  • Somatic mutations and reduced expression of TET family members are prevalent in various malignancies, particularly hematological neoplasms.
  • DNA methylation dynamics are critical for cellular proliferation and differentiation, highlighting the significance of TET enzyme function.

Purpose of the Study:

  • To review the structure and function of the TET2 enzyme.
  • To explore TET2's interactions with cooperating mutations and small molecules.
  • To elucidate TET2's role in aberrant hematopoiesis.

Main Methods:

  • Genomic analyses to identify TET family mutations and expression levels.
  • Biochemical assays to study enzyme activity and interactions.
  • Literature review of existing research on TET2 in hematopoiesis.

Main Results:

  • TET2 mutations and altered expression are common in hematological malignancies.
  • TET2 plays a critical role in regulating DNA methylation.
  • TET2 interacts with various proteins and small molecules that influence its function.

Conclusions:

  • TET2 is a crucial tumor suppressor in hematopoiesis.
  • Dysregulation of TET2 contributes to the development of blood cancers.
  • Targeting TET2 may offer therapeutic strategies for hematological neoplasms.